Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

Model scores of the 29,894 trials active now.

Model score 37% for any early termination, 24% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mripatients mustcarcinomagreater thanevidence of
  Phrases that lowered it: within 1414 dayshormonestudyassess
• Sponsor's past termination rate: 15.4% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 56 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 23.5% (raises risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 78 (raises risk) · Sponsor's track record
• Allocation: randomized (lowers risk) · Design
• Keywords listed: 2 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 95.3% (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores NCT00832338 · started 2009 · scored riskier than 99% of active trials terminated
• A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer NCT00789581 · started 2008 · scored riskier than 60% of active trials completed
• TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer NCT01354522 · started 2011 · scored riskier than 25% of active trials completed
• Dose Dense TC + Pegfilgrastim Support for Breast Cancer NCT01671319 · started 2011 · scored riskier than 99% of active trials completed
• DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer NCT03154749 · started 2016 · scored riskier than 73% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.